HOME >> BIOLOGY >> NEWS
New joint replacement material developed at MGH put to first clinical use

Massachusetts General Hospital (MGH) surgeons have performed the first total hip replacement using a joint socket lined with a novel material invented at the MGH. An advance over first-generation highly crosslinked polyethylene, which was also developed at MGH and significantly reduced a serious complication of early hip implants, the new material may be applied in replacements for a wider variety of joints in a more diverse group of patients.

We think this material could be used for any joint in the body and in any implant design, even those demanding higher flexion and more mobility, says Orhun Muratoglu, PhD, co-director of the Harris Orthopdics Biomechanics and Biomaterials Laboratory (OBBL) at MGH, who developed the new material in collaboration with scientists at the Cambridge Polymer Group.

Total replacements for hips and other joints were developed in the late 1960s, but it soon became apparent that hip implants could start loosening about 5 years after surgery and would eventually fail completely. A team led by William Harris, MD, DSc, now director emeritus of the MGH OBBL, investigated this complication and found that long-term friction of the implants head against the polyethylene-lined joint socket would break off small particles of polyethylene. The bodys immune system reacted against these foreign particles, eventually destroying adjacent bone tissue and causing the implant to loosen a condition called periprosthetic osteolysis.

Harris and his colleagues, working with polymer chemists from MIT, found that high doses of radiation would crosslink the polyethylene, bonding molecules together to produce a much more durable material. The procedure also generates free radicals that could lead to oxidization and degradation of the implant, but the research team found that melting the material would eliminate free radicals. The first-generation highly crosslinked polyethylene was approved by the FDA for use in implants
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
23-Jul-2007


Page: 1 2

Related biology news :

1. It takes a village -- female ducks negotiate joint rearing of ducklings
2. Brown and OTS will jointly manage new ILTER network secretariat
3. How movement lubricates bone joints
4. Gene therapy research switches off joint inflammation; switches on genetic process of joint repair
5. New evidence shows Rituximab halts damage to joints
6. Healthy fruits, vegetables highlight joint medical, agricultural research meet in Texas
7. Brookhaven Lab and Mount Sinai form joint Center for Translational Biomedical Imaging
8. Biodesign and TGen form joint Center for Systems and Computational Biology
9. $1 million grant from Howard Hughes Medical Institute to fund joint neuroscience program
10. Phytochemicals may protect cartilage, prevent pain in joints
11. UCSD medical/bioengineering reseachers show titanium debris satobtage artificial joints

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New joint replacement material developed MGH put first clinical use

(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... 2015 Research and ... of the "Global Biosimilars Market, 2015 - ... The Global Biosimilars Market, 2015 - 2025, report ... biosimilars market. With the blockbuster biologics losing patent ... biosimilars are being viewed as viable substitutes to ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: